|
Name of Grantee |
Development Phase Supported |
Environmental and Health Risk Management Plan (EHRMP) |
|
Cadila Healthcare Ltd |
Up to Phase I |
Click Here |
|
Bharat Biotech International Ltd |
Up to Phase I |
Coming Soon
|
|
Serum Institute of India Pvt Ltd |
Phase III |
Click Here |
|
Aurobindo Pharma Ltd |
Phase I/II CT |
Click Here |
|
Biological E Ltd |
Phase I CT |
Click Here |
|
Seagull Biosolutions Pvt Ltd |
Efficacy studies of the AV-S using ACE2+ Mice |
Click Here Click Here |
|
Intas Pharmaceuticals |
Pre-clinical cytotoxicity and long-term efficacy study in Balb/c mice. |
Click Here |
|
Enzene Biosciences Pvt. Ltd |
Large scale production of spike protein and sub-domains of SARS-Cov-2 for diagnostic purpose. |
Click Here |
|
National Institute of Immunology |
Animal model for evaluation of SARS-CoV-2 vaccines |
Click Here |
|
Sahajanand Laser Technology Ltd |
Proof of concept for evaluation for the antigenicity of COVID-19 DNA vaccine candidates in vivo for its ability to induce efficient immune responses post immunization using electroporation |
Click Here Click Here |